Hormone Receptor–Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers
In conclusion, HR+/MP-H2 cancers closely resemble TN breast cancers in transcriptional and clinical features and benefit from similar treatment strategies.
Authors
- Rita Nanda (ORCID: https://orcid.org/0000-0001-5248-0876)
- Denise M. Wolf (ORCID: https://orcid.org/0000-0002-3676-653X)
- Rolando García-Milian (ORCID: https://orcid.org/0000-0003-1557-566X)
- Laura van ‘t Veer (ORCID: https://orcid.org/0000-0002-9838-8298)
- Laura A. Huppert (ORCID: https://orcid.org/0000-0002-8512-5608)
- Lajos Pusztai (ORCID: https://orcid.org/0000-0001-9632-6686)
- Alejandro Ríos-Hoyo (ORCID: https://orcid.org/0000-0001-5344-9168)
- Christina Yau (ORCID: https://orcid.org/0000-0002-1937-0859)
- Laura J. Esserman (ORCID: https://orcid.org/0000-0001-9202-4568)
- Erin F. Cobain (ORCID: https://orcid.org/0000-0001-9602-8611)
- Gillian L. Hirst (ORCID: https://orcid.org/0000-0002-4502-0035)
- Michał Marczyk (ORCID: https://orcid.org/0000-0003-2508-5736)
- Jiawei Dai (ORCID: https://orcid.org/0000-0003-3806-5160)
- Kaitlyn Xiong (ORCID: https://orcid.org/0000-0001-9764-6745)
Institutions
- Silesian University of Technology (PL)
- University of California, San Francisco (US)
- University of Michigan (US)
- Whitney Museum of American Art (US)
- Yale Cancer Center (US)
- Yale University (US)
- University of Illinois Chicago (US)
- University of New Haven (US)
- University of Chicago (US)
- Michigan United (US)
- Michigan Medicine (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of San Francisco (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1553
- Citations
- 6
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Clovis Oncology
- Syndax Pharmaceuticals
- Moderna
- Seagen
- Natera
- Eisai
- Genentech